Limiting the discretion of the Patent Trial and Appeal Board (PTAB) in relation to inter partes reviews (IPRs) is a game-changing decision which creates a procedural “mess”, one lawyer has claimed.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
24 April 2018 In a much-awaited judgment the US Supreme Court has confirmed that the Patent Trial and Appeal Board (PTAB) cannot choose to review only some challenged claims in an inter partes review—it must assess them all.
9 July 2020 FitBit has taken advantage of the US Supreme Court’s SAS Institute ruling to score a major patent victory at the US Court of Appeals for the Federal Circuit.